Enapril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enapril

Quick Facts

Property Description
Active ingredient Enalapril Maleate
Form Tablet (Oral), Solution (Oral/IV form is Enalaprilat)
Pharmacological class Angiotensin-Converting Enzyme Inhibitor (ACE inhibitor)
Common purpose Lowering high blood pressure (antihypertensive effect)
Origin Synthetic, Prodrug

What Type of Medicine is Enapril?

Enapril is an oral medication containing the active component Enalapril Maleate, which is classified in the pharmacological group of Angiotensin-Converting Enzyme Inhibitors (ACE inhibitors). This classification defines its primary mechanism of action: interfering with a key biological pathway responsible for regulating blood pressure. Enalapril is an antihypertensive agent used to lower high blood pressure. The medicine's core function is to manage and reduce elevated pressure within the circulatory system, a function that is clinically recognized and supported by pharmacological studies.

Enalapril is a synthetic compound and is designated as a prodrug, meaning it remains largely inactive until it is converted by the liver into its potent, working form, Enalaprilat. This conversion is a critical step for the drug's efficacy, as the body must process the pill to gain the intended benefit.


Composition, Forms, and General Purpose

The core composition of this medicine relies on the active component, Enalapril Maleate, which is typically available for oral administration in the tablet dosage form. As an INN (International Nonproprietary Name) compound, Enalapril is the active ingredient in several popular preparations globally, confirming its established use within the medical community. It is supplied both as a single-ingredient product and in fixed-dose combination products that may integrate an additional component, typically a diuretic, to further enhance its effect. The general therapeutic purpose of Enalapril is to reduce the resistance in the blood vessels, allowing them to relax and widen. This action fundamentally helps to lower high blood pressure and, consequently, alleviate the workload placed on the heart and the cardiovascular system, making it a foundational treatment for managing the long-term stress on the heart.

What side effects are possible with Enapril?

Possible Side Effects and Safety Information

The official safety profile of Enapril (Enalapril Maleate) defines a range of possible adverse reactions, classified according to their documented frequency and the physiological systems affected. This information is derived from government regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by how commonly they are observed, consistent with regulatory reporting standards:

  • Very Common (Affecting ge 1 in 10 patients): Cough, dizziness, headache, asthenia (lack of energy), and blurred vision.
  • Common (Affecting ge 1 in 100 but <1 in 10 patients): Symptomatic hypotension, chest pain, fatigue, nausea, diarrhea, rash, and elevations in serum creatinine and serum potassium (hyperkalaemia).
  • Uncommon (Affecting ge 1 in 1,000 but <1 in 100 patients): Palpitations, insomnia, confusion, constipation, dry mouth, and renal dysfunction.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights several serious, though rare, adverse reactions and specific constraints on use.

  • Serious Reactions: The most critical documented risk is angioedema, involving rapid swelling of the face, tongue, glottis, or larynx. Other serious reactions include hepatic failure (which can be fatal) and blood dyscrasias such as neutropenia.
  • Population-Specific Constraints: Enapril is officially contraindicated during pregnancy due to the risk of fetal toxicity, which includes injury and death to the developing fetus. Use is also restricted in patients with severe impaired renal function or in combination with certain other cardiovascular medications, such as Aliskiren in diabetic patients.
  • Time-Related Pattern: Symptomatic hypotension is noted in official documents as being most likely to occur at the initiation of treatment.

The regulatory documentation emphasizes monitoring parameters, such as serum creatinine and serum potassium levels, to manage potential systemic adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define an overdose of Enapril as potentially leading to severe hypotension (low blood pressure), which is the most prominent manifestation. Other documented signs and symptoms associated with overexposure include fainting (syncope), lightheadedness, and sleepiness.


Immediate Actions

It is imperative to seek immediate medical attention or call a poison control center right away if an overdose is suspected or confirmed. Do not wait for symptoms to develop. Severe outcomes necessitate swift action.

Emergency services (e.g., 911) should be called immediately if the individual has collapsed, is experiencing trouble breathing, has had a seizure, or cannot be awakened.

Management and Monitoring

Management described in official prescribing information is primarily supportive, aimed at correcting severe hypotension. Enalaprilat, the active metabolite of Enapril, is known to be dialyzable from the systemic circulation, which may be employed as a management strategy in severe cases. An overdose results from ingesting amounts significantly greater than the prescribed dose, and the resulting manifestations are considered an extension of the drug's therapeutic effect on blood pressure.

Therapeutic Uses of Enapril

What Enapril Treats: Main Uses and Benefits

Enapril is commonly used in the long-term management of systemic high blood pressure (hypertension), which is a condition involving symptoms related to heightened physiological activity. This medication is utilized to address conditions such as chronic hypertension, symptomatic heart failure, and certain types of diabetic kidney disease.

Enalapril is generally considered relevant in conditions marked by chronic elevated vascular pressure. By supporting the reduction of this pressure, it contributes to easing the overall symptom load of hypertension, which is applied in addressing the typically asymptomatic burden on the cardiovascular system. The central benefit supports general well-being by addressing the risk associated with prolonged physiological stress. It offers supportive therapeutic benefit for patients with chronic heart failure, helping to address symptom clusters that interfere with daily functioning, such as fatigue and shortness of breath. It also plays a role in managing patients with asymptomatic reduced heart function.


Quick Fact: Relief for Systemic Pressure Burden

Condition Category Primary Benefit Provided
Hypertension Supports long-term vascular health
Heart Failure Assists in easing fatigue and shortness of breath
Kidney Disease Contributes to managing protein loss (proteinuria)

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that is subject to specific usage rules defined by regulatory bodies.

Populations for Whom Use is Contraindicated

Official labeling prohibits the use of Enalapril in the following groups:

  • Patients with a history of angioedema (severe swelling of the face, tongue, or throat) related to previous ACE inhibitor treatment, or with hereditary/idiopathic angioedema.
  • Pregnant women in the second and third trimesters, as it can cause harm or death to the developing fetus.
  • Patients with diabetes who are also taking a medicine containing aliskiren.
  • Patients taking a neprilysin inhibitor (such as sacubitril) or within 36 hours of taking this drug class.

Age and Condition-Specific Eligibility

The medicine is generally not recommended for:

  • Neonates (infants one month of age or less).
  • Pediatric patients with a glomerular filtration rate (GFR) less than 30 mL/min/1.73 m^2 due to insufficient data on safety and efficacy.

Use during breastfeeding is generally not recommended, and a risk-benefit assessment is advised. Patients must discontinue use immediately if pregnancy is detected.

What should I know about interactions with other medicines?

Enapril’s official interaction profile is structured around combinations classified as either formally contraindicated or clinically significant, based on documentation from regulatory authorities.


Contraindicated Combinations and Timing Rules

Co-administration with Sacubitril/Valsartan is explicitly prohibited due to the heightened risk of angioedema. A mandatory 36-hour separation window is strictly required when switching a patient to or from Sacubitril/Valsartan administration. Use of Enapril is also contraindicated with Aliskiren in patients diagnosed with diabetes mellitus or those having documented renal impairment where the Glomerular Filtration Rate (GFR) is less than 60 mL/min/1.73 m^2. This restriction addresses the established risk of adverse outcomes from dual inhibition of the Renin-Angiotensin System (RAS).


Pharmacodynamic and Exposure Outcomes

A major interaction domain is the risk of hyperkalemia (elevated serum potassium levels) when Enapril is co-administered with potassium-sparing diuretics or potassium supplements. Concomitant use with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may result in a reduced antihypertensive effect and increases the risk of acute renal function deterioration. This particular risk is formally noted as heightened in elderly or volume-depleted populations. Enapril co-administration also leads to increased serum concentrations of Lithium, which elevates the risk of toxicity. Finally, the official profile documents that food has no influence on the drug’s absorption, while the risk of dizziness may be increased when alcohol is consumed.

Mechanism of Action

Enapril is an Angiotensin-Converting Enzyme (ACE) inhibitor and a prodrug. Upon ingestion, it undergoes hydrolysis to form its active metabolite, enaprilat. Enaprilat functions by competitively binding to the active site of the ACE enzyme, primarily located on the luminal surface of endothelial cells, especially within the pulmonary and renal vasculature.

This binding event prevents the ACE enzyme from catalyzing the cleavage of Angiotensin I into the potent vasoconstrictor and secretagogue, Angiotensin II. By interrupting this key step in the Renin-Angiotensin-Aldosterone System (RAAS), enaprilat reduces the systemic concentration of Angiotensin II.

The resulting decrease in Angiotensin II leads to two primary physiological effects: a reduction in its direct vasoconstrictive effect on arterioles, which facilitates peripheral vascular widening, and decreased stimulation of aldosterone secretion from the adrenal cortex. The reduced aldosterone level diminishes the kidney's tubular reabsorption of sodium and water. These combined intracellular and systemic modulations regulate overall fluid dynamics and vascular tone.

Dosage and Administration Information

Enalapril is an orally administered medication, typically available as a tablet in strengths ranging from 2.5 mg to 20 mg, though the active metabolite, Enalaprilat, may be utilized via the intravenous route in acute care settings where oral therapy is impractical. The usage pattern for adults with hypertension generally starts with an initial dose of 5 mg taken once daily, which is subsequently adjusted toward a maintenance range of 10 mg to 40 mg, with the maximum daily dose established at 40 mg. Conversely, the regimen for heart failure begins with a lower starting dose of 2.5 mg, taken once or twice daily. This initial dose is followed by a gradual increase, or titration, over a period of weeks to reach a target maintenance dose, with a maximum limit of 40 mg total daily, often administered in two divided doses.

The oral medication may be taken either with or without food, as absorption is not significantly affected by meals. There are population-specific adjustments to the dosing schedule: a dose reduction to an initial 2.5 mg once daily is necessary for adult patients presenting with moderate-to-severe renal impairment (Creatinine Clearance leq 30 mL/min). A lower starting dose is also recommended when initiating therapy in patients already receiving diuretics. Furthermore, the first dose administered for heart failure requires close medical supervision to monitor physiological response. If an oral dose is missed, the patient should skip the missed dose and resume the regular schedule without taking an extra amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Enapril

This overview describes the types of research and general findings for Enapril as reported in official scientific literature and regulatory documents. It is intended to help contextualize the evidence but does not offer medical advice, dosing instructions, or safety information.


Evidence from Randomized Trials for High Blood Pressure (Hypertension)

Research exploring the use of Enapril for high blood pressure was evaluated primarily through large, randomized controlled trials (RCTs) and comprehensive systematic reviews. These studies examined the drug in adults with various forms of essential hypertension. The researchers monitored key outcomes such as the measured change in systolic and diastolic blood pressure values over time. They also tracked the long-term patterns of incidence of major cardiovascular events, such as stroke or heart attack.

Studies monitored how blood pressure changed in the observed populations when Enapril was compared to both inactive placebo pills and other types of blood pressure medications. Findings describe patterns observed in the studies related to how the blood pressure values changed in the tested cohorts.

However, the evidence quality varies across studies when comparing long-term patient outcomes directly against every other major drug class used for hypertension. Additionally, research indicates that the measured effect on blood pressure may differ across various racial or ethnic subgroups when Enapril is used as a sole medication.


Core Research in Symptomatic Heart Failure

The main evidence for Enapril in heart failure was observed in landmark, large-scale, placebo-controlled trials conducted in adults diagnosed with symptomatic heart failure who also have reduced left ventricular function. These studies focused on outcomes reflecting daily functioning and outcomes related to systemic or functional imbalance. Researchers monitored critical endpoints such as all-cause mortality and the frequency of hospitalization for heart failure exacerbation.

Findings describe patterns observed in the studies, reporting the measured rates of hospitalization and survival in the studied groups. The evidence contributes to understanding symptom patterns. These pivotal trials typically studied Enapril when it was used concurrently with other established heart failure therapies, such as diuretics.

What remains uncertain is the drug's role in a condition known as Heart Failure with Preserved Ejection Fraction (HFpEF). Furthermore, data for Enapril when used as the only medication in patients with advanced heart failure is limited, as the evidence often stems from combination therapy trials.

Key Studies & References

  1. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
  2. Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients—A Systematic Review (informing pediatric PK data and safety profile).
  3. Enalapril - StatPearls (Overview of FDA-approved indications and associated clinical evidence).

Frequently Asked Questions (FAQ)

Common questions about Enapril (FAQ)


Q: How long does Enapril take to start working for blood pressure?

A: According to official product information, the reduction in blood pressure usually begins within one hour after taking a dose. The drug’s peak blood pressure lowering activity is often measured within 4 to 6 hours.

Q: Can Enapril be taken at night instead of in the morning?

A: Official regulatory documents generally specify that the medication is taken once or twice daily, but they do not explicitly mandate a specific time (morning or night). Since the anti-hypertensive effect is maintained for at least 24 hours, the timing of the dose is often determined based on the prescription and patient needs.

Q: Does Enapril cause weight gain or weight loss?

A: Weight change is not reported as a common, independent side effect in the official product information. However, weight gain may be observed as a symptom associated with more serious adverse effects, such as fluid retention or certain kidney problems. Monitoring for symptoms associated with fluid retention is a routine part of managing this therapy.

Q: Why do some people need to switch from Enapril to a different medication?

A: One of the most common reasons for discontinuing Enapril is the development of a persistent nonproductive cough, which is a known side effect of ACE inhibitors. Switching may also be necessary if a patient experiences angioedema (severe swelling of the face, tongue, or throat), a rare but serious adverse reaction. If a bothersome cough develops, regulatory information notes this as a known cause for the medication to be potentially changed.

Q: Do I need to change my diet while on Enapril?

A: Regulatory documents suggest that patients should use caution with or avoid potassium-containing salt substitutes and potassium supplements. This is because the drug can increase the risk of hyperkalemia (high potassium levels) in the blood, and these products may worsen that effect.

Q: Does Enapril affect kidney function over time?

A: Official information indicates that the drug can be associated with a risk of kidney function deterioration or acute renal failure, particularly when combined with certain other medications like NSAIDs. Frequent monitoring of kidney function is a required part of managing this treatment.

Q: Can Enapril cause a persistent dry cough?

A: Yes, a persistent nonproductive cough is recognized as a common side effect of Enapril and all medications in the Angiotensin-Converting Enzyme (ACE) inhibitor class. If a bothersome cough develops, regulatory information notes this as a factor to be considered in the overall treatment plan.

Q: Can older adults use Enapril?

A: Yes, older adults may be prescribed Enapril. However, official information notes that close medical monitoring is often a consideration for this population. Regulatory guidelines indicate that older adults may process drugs more slowly, and therefore may require a lower starting dose or a different dosing schedule.

Q: What are the signs of an allergic reaction to Enapril?

A: The most critical documented serious reaction is angioedema, which involves rapid swelling of the face, lips, tongue, or throat, potentially causing difficulty breathing. Other signs of a hypersensitivity reaction can include generalized hives, itching, or a rash.

Q: Does Enapril interact with common pain relievers like ibuprofen?

A: Official labeling warns that combining Enapril with ibuprofen (a Nonsteroidal Anti-inflammatory Drug, or NSAID) may lead to a reduction in the blood pressure-lowering effect. Furthermore, this combination significantly increases the risk of kidney damage, especially in older patients or those with pre-existing kidney conditions.

Q: Does taking Enapril mean I have to limit my potassium intake?

A: Regulatory warnings indicate a risk of hyperkalemia (elevated serum potassium levels) with this medication. For this reason, regulatory warnings caution against the use of potassium supplements and potassium-containing salt substitutes.

Q: Can Enapril be stopped suddenly?

A: The abrupt withdrawal of this medication has not been associated with a rapid or rebound increase in blood pressure, according to regulatory documentation. However, changes to a chronic medication regimen are typically managed by a healthcare provider.

Q: What happens if I accidentally take too much Enapril?

A: The most common clinical sign of an overdose is severe hypotension (very low blood pressure) and can be accompanied by dizziness and fainting. Overdose management focuses on supportive care for severe hypotension and may involve medical intervention like the administration of intravenous fluids.

Q: Does Enapril affect blood sugar levels?

A: When Enapril is used at the same time as anti-diabetic agents (drugs for managing diabetes), there is a possible risk of hypoglycemia (low blood sugar). This effect is noted to be more likely during the first month of combined use or in patients who have renal impairment.

Q: Is Enapril used for anything other than high blood pressure and heart failure?

A: Yes, in addition to its main uses, official indications include its recommendation for managing diabetic nephropathy and microalbuminuria (protein in the urine) in patients with diabetes. This use is intended to help reduce the risk of further kidney problems related to the diabetic condition.

Q: Will Enapril interfere with any supplements I'm taking?

A: There is an explicit warning to use caution with or avoid potassium supplements due to the risk of high potassium in the blood. For many other herbal and complementary remedies, regulatory bodies indicate there is not enough information to confirm safety or interaction profiles.

Q: Why is Enapril sometimes prescribed with a diuretic (water pill)?

A: Diuretics are frequently prescribed alongside Enapril to help increase the overall blood pressure-lowering (hypotensive) effect. This combination was also used in major clinical trials and has been shown to help manage fluid balance in heart failure, leading to reduced heart size.

Q: How often do I need follow-up appointments when taking Enapril?

A: Regulatory guidelines require frequent patient monitoring after treatment begins or after a dosage adjustment. This monitoring typically includes checking blood pressure, renal function, and serum potassium levels as a standard part of managing systemic effects.

Q: Are there any long-term effects of taking Enapril that I should know about?

A: Long-term clinical trials have shown positive outcomes, including a reduction in hospitalization for heart failure exacerbation and a reduction in all-cause mortality in specific patient groups. Long-term monitoring of kidney function is a standard safety measure during continued therapy.

Q: Is it common for doctors to adjust the dose of Enapril after starting?

A: Yes, according to official prescribing information, the dosage is initially started low and then adjusted or titrated over a period of weeks. This process is necessary to slowly and safely reach a patient's individualized target maintenance dose for both hypertension and heart failure.

Q: Is Enapril generally considered safe for people with liver conditions?

A: The drug is associated with rare cases of hepatic failure (severe liver damage), and its use should be considered cautiously in patients with pre-existing liver problems. Monitoring of liver function is generally advised during treatment to detect any adverse reactions.

Q: Can children or teenagers be prescribed Enapril?

A: Official documents indicate that Enapril is approved for hypertension in children 1 month to 16 years old. However, it is not recommended for treating heart failure or for children with severe kidney disease.

Q: What is the expected outcome of treatment with Enapril?

A: Expected outcomes of treatment, based on clinical studies, include the reduction of high blood pressure to target goals. In heart failure, the outcomes include retarding cardiac enlargement (reducing heart size) and a significant reduction in hospitalization rates.

Q: What is the half-life of Enapril in the body?

A: Pharmacokinetic data shows that the effective half-life for accumulation of the active form, enalaprilat, following multiple oral doses, is approximately 11 hours. This measurement helps define the drug's sustained effect in the body.

Q: What are the guidelines regarding Enapril and breastfeeding?

A: Official labeling states that the medication passes into breast milk and may cause side effects in the nursing infant. The decision whether to continue breastfeeding or stop taking the medication should be determined in consultation with a healthcare provider.

Q: Why is it important to check blood pressure regularly while taking Enapril?

A: Regulatory documents emphasize that regular blood pressure checks are essential to detect hypotension (low blood pressure) and related symptoms, especially after starting the drug. This monitoring helps in managing the dosage and assessing progress toward the therapeutic blood pressure goal.

Q: Does Enapril affect sleep patterns?

A: Official adverse reaction reports indicate that insomnia (difficulty sleeping) has been reported as an uncommon side effect of the medication. This is a factor that may be considered during the overall management of the condition.

How should Enapril be stored and disposed of?

Enalapril Storage and Disposal According to Official Labeling

Enalapril maleate tablets must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), and kept in a tightly closed container protected from moisture. Storage for tablets must not exceed 25 C in some packaging.

Enalapril Oral Solution (reconstituted) must not be frozen. It can be stored refrigerated (2 C to 8 C) until the expiration date, or at controlled room temperature, but must be discarded after 60 days from the dispensing date if kept at room temperature.

All forms of Enalapril must be kept out of the reach of children. Unused or expired medication should be disposed of by consulting a healthcare professional for guidance on local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enapril found in:

A-Z Index: